{"organizations": [], "uuid": "79fc1d556057e635ca8a5b77983b574cca041151", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-glycomimetics-enters-agreement-wit/brief-glycomimetics-enters-agreement-with-hovon-to-initiate-study-startup-activities-for-planned-clinical-trial-of-gmi-1271-and-decitabine-idUSASB0C4TA", "country": "US", "domain_rank": 408, "title": "BRIEF-Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.946, "site_type": "news", "published": "2018-02-08T22:26:00.000+02:00", "replies_count": 0, "uuid": "79fc1d556057e635ca8a5b77983b574cca041151"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-glycomimetics-enters-agreement-wit/brief-glycomimetics-enters-agreement-with-hovon-to-initiate-study-startup-activities-for-planned-clinical-trial-of-gmi-1271-and-decitabine-idUSASB0C4TA", "ord_in_thread": 0, "title": "BRIEF-Glycomimetics Enters Agreement With Hovon To Initiate Study Startup Activities For Planned Clinical Trial Of GMI-1271 And Decitabine", "locations": [], "entities": {"persons": [{"name": "hovon", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "glycomimetics inc", "sentiment": "neutral"}, {"name": "aml", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Glycomimetics Inc:\n* GLYCOMIMETICS ENTERS INTO AGREEMENT WITH HOVON TO INITIATE STUDY STARTUP ACTIVITIES FOR PLANNED CLINICAL TRIAL OF GMI-1271 AND DECITABINE IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE UNFIT FOR CHEMOTHERAPY\n* GLYCOMIMETICS INC - ‍ON TRACK TO DISCLOSE DETAILS FOR DESIGN OF PHASE 3 TRIAL IN RELAPSED/REFRACTORY AML PATIENTS DURING 2017 YEAR-END EARNINGS CALL\n* GLYCOMIMETICS INC - ‍ HOVON INTENDS TO ENROLL APPROXIMATELY 140 PATIENTS IN CLINICAL TRIAL OF GMI-1271 AND DECITABINE​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T22:26:00.000+02:00", "crawled": "2018-02-09T16:38:15.000+02:00", "highlightTitle": ""}